The Difference Between Bedaquiline Fumarate (Snaery) and Delamanid

Bedaquiline fumarate (Bedaquiline) and delamanid (Delamanid) are both drugs used to treat multidrug-resistant tuberculosis (MDR-TB), but they have some differences in chemical structure, pharmacological effects, clinical application and safety. A detailed comparison of these two drugs follows:

1.Chemical structure:

Fumaric acidBedaquiline (Snery) (Bedaquiline): Fumaric acid Bedaquiline (Snery) is a compound based on an amide skeleton, and its chemical name is span>(1R,2S)-1-(6-bromo-2-methoxy-quinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yloxy)butan-2-ol. It belongs to the carbamate class of drugs.

Delamanid (Delamanid): Delamanid is a new anti-tuberculosis drug, its chemical name is(N′-[2,6-dimethyl-3-([1,1′-biphenyl]-4-yloxy)phenyl]-[1,1′-biphenyl]-4-carboxamide). It is a benzophenone derivative.

2.Pharmacological effects:

Fumaric acidBedaquiline (Snaery) : Fumaric acidBedaquiline (Snaery) mainly exerts its anti-tuberculosis effect by inhibiting the activity of ATP synthase (ATP synthase), thereby blocking the growth and proliferation of Mycobacterium tuberculosis.

Delamanid: Delamanid exerts its anti-tuberculosis effect by inhibiting the activity of amino acid decarboxylase (dihydrofolate reductase), thereby blocking the cell wall synthesis of Mycobacterium tuberculosis.

3.Clinical application:

Fumaric acidBedaquiline (Snaery) : Fumaric acid Bedaquiline (Snaery) is one of the first-line drugs recommended by the World Health Organization (WHO) for the treatment of MDR-TB. It is often used in combination with other anti-TB drugs to treat TB bacteria that are resistant to conventional treatment regimens.

Delamanid: Delamanid is also one of the drugs recommended by the WHO to treat MDR-TB and is often used as part of a second-line treatment regimen. It is used in combination with other anti-tuberculosis drugs to treat tuberculosis bacteria that are resistant to conventional treatment regimens.

4.Drug resistance:

Fumaric acidBedaquiline (Snaeryx) : Although fumaric acidBedaquiline (Snaeryx) is an effective anti-tuberculosis drug, some TB bacteria have become resistant to it. Therefore, when using fumaric acidbedaquiline (Sneril) it is necessary to carefully monitor resistance and adjust the treatment plan as necessary.

Delamanid: The resistance to delamanid is relatively rare, but there are also reports that some tuberculosis bacteria have become resistant to it. Therefore, drug resistance needs to be closely monitored when using delamanid and the treatment regimen adjusted as needed.

5.Adverse events:

Fumaric acidBedaquiline (Snaery) : Common adverse events of fumaric acidBedaquiline (Snaery) include nausea, vomiting, headache, joint pain, arrhythmia, etc. Serious adverse events may include visual disturbances, cardiac abnormalities, and liver function abnormalities.

Delamanid: Common adverse events of delamanid include nausea, vomiting, diarrhea, joint pain, etc. Serious adverse events may include vision loss, cardiac arrhythmias, and liver function abnormalities.

6.Treatment plan:

Fumaric acid Bedaquiline (Sneril) and delamanid are often used as part of a treatment regimen for MDR-TB, but specific treatment regimens need to be customized based on the individual patient's circumstances and resistance profile.

In summary, although fumaric acidbedaquiline (Sneril) and delamanid are both important drugs for the treatment ofMDR-TB, they have some differences in chemical structure, pharmacological effects, clinical applications and adverse events. Doctors need to comprehensively consider the patient's condition and drug resistance when selecting a treatment plan, and use these two drugs rationally according to the specific situation.